Short-Term Efficacy and Safety of Desvenlafaxine in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

Kornstein, Susan G.; Jiang, Qin; Reddy, Sujana; Musgnung, Jeff; Guico-Pabia, Christine J.

doi:10.4088/jcp.10m06018blu

Cited by 43 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only desvenlafaxine has been specifically evaluated through randomized, placebo-controlled trials for antidepressant efficacy in peri-and postmenopausal depressed women; the 2 trials found that desvenlafaxine (50 mg daily, N ¼ 434 91 ; 100 mg and 200 mg daily, N ¼ 387 92 ) was superior to placebo. Importantly, a post-hoc analysis of these RCTs showed no differences in treatment response to desvenlafaxine between peri-and postmenopausal women.…”

Section: Is Antidepressant Medication Effective During Menopause?mentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

et al. 2016

View full text Add to dashboard Cite

Methods: Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. This section on ''Special Populations'' is the sixth of six guidelines articles.Results: Recent studies inform the treatment of MDD in children and adolescents, pregnant and breastfeeding women, women in perimenopause or menopause, and the elderly. Evidence for efficacy of treatments in these populations is more limited than for the general adult population, however, and risks of treatment in these groups are often poorly studied and reported. Conclusions: Despite the limited evidence base, extant data and clinical experience suggest that each of these special populations can benefit from the systematic application of treatment guidelines for treatment of MDD.

show abstract

Section: Is Antidepressant Medication Effective During Menopause?mentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Antidepressants remain the first line pharmacological treatment for depression in peri- and postmenopausal women. Only desvenlafaxine has been studied sufficiently and proven efficacious for peri- and postmenopausal depression in two large RCTs (Clayton, 2013; Kornstein, 2010). However, there are also small open label studies that suggest efficacy for SSRIs, SNRIs and vortioxetine (Maki et al, 2019).…”

Section: Complex Presentations and Special Populationsmentioning

confidence: 99%

The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders

Malhi

Bell

Bassett³

et al. 2020

Aust N Z J Psychiatry

312

365

View full text Add to dashboard Cite

Objectives: To provide advice and guidance regarding the management of mood disorders, derived from scientific evidence and supplemented by expert clinical consensus to formulate s that maximise clinical utility. Methods: Articles and information sourced from search engines including PubMed, EMBASE, MEDLINE, PsycINFO and Google Scholar were supplemented by literature known to the mood disorders committee (e.g. books, book chapters and government reports) and from published depression and bipolar disorder guidelines. Relevant information was appraised and discussed in detail by members of the mood disorders committee, with a view to formulating and developing consensus-based recommendations and clinical guidance. The guidelines were subjected to rigorous consultation and external review involving: expert and clinical advisors, key stakeholders, professional bodies and specialist groups with interest in mood disorders. Results: The Royal Australian and New Zealand College of Psychiatrists mood disorders clinical practice guidelines 2020 (MDcpg2020) provide up-to-date guidance regarding the management of mood disorders that is informed by evidence and clinical experience. The guideline is intended for clinical use by psychiatrists, psychologists, primary care physicians and others with an interest in mental health care. Conclusion: The MDcpg2020 builds on the previous 2015 guidelines and maintains its joint focus on both depressive and bipolar disorders. It provides up-to-date recommendations and guidance within an evidence-based framework, supplemented by expert clinical consensus. Mood disorders committee: Gin S Malhi (Chair), Erica Bell, Darryl Bassett, Philip Boyce, Richard Bryant, Philip Hazell, Malcolm Hopwood, Bill Lyndon, Roger Mulder, Richard Porter, Ajeet B Singh and Greg Murray.

show abstract

“…Most other antidepressants have been trialled in cohorts of younger premenopausal or older postmenopausal women. 38,39 Clinical trials have shown that compared to placebo, antidepressants can help to reduce the frequency of VMS 40,41 ; however, compared to HRT they are much less effective. HRT has been shown to reduce the severity and frequency of VMS by up to 83%, whereas antidepressants reduced the severity by up to 50%.…”

Section: Treatmentmentioning

confidence: 99%

Low mood and depressive symptoms during perimenopause – Should General Practitioners prescribe hormone replacement therapy or antidepressants as the first-line treatment?

Leonhardt¹

2019

Post Reprod Health

View full text Add to dashboard Cite

Perimenopausal women have an increased risk of developing new onset and recurrent mental health conditions such as anxiety, low mood and depressive symptoms. General Practitioners frequently prescribe antidepressants as the first-line treatment for these symptoms, despite clear lack of evidence for their efficacy and their unfavourable side effect profile. This article, written by a General Practitioner, gives a practical overview of the mental health symptoms which women may report to their General Practitioners during the menopausal transition and discusses underlying causes, assessment, risk factors and treatment options based on current evidence.

show abstract

Short-Term Efficacy and Safety of Desvenlafaxine in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

Abstract: clinicaltrials.gov Identifier: NCT00369343.

Cited by 43 publications

References 0 publications

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders

Low mood and depressive symptoms during perimenopause – Should General Practitioners prescribe hormone replacement therapy or antidepressants as the first-line treatment?

Contact Info

Product

Resources

About